Obstructive Sleep Apnea (OSA)- Market Insights, Epidemiology and Market Forecast-2027
This report can be delivered to the clients within 24 hours
DelveInsight’s ‘Obstructive Sleep Apnea (OSA)- Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Obstructive Sleep Apnea (OSA) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
Obstructive Sleep Apnea (OSA) - Disease Understanding and Treatment Algorithm
The DelveInsight Obstructive Sleep Apnea (OSA) market report gives the thorough understanding of the Obstructive Sleep Apnea by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Obstructive Sleep Apnea in the US, Europe, and Japan.
Obstructive Sleep Apnea Epidemiology
The Obstructive Sleep Apnea (OSA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Prevalent cases by Age Group, Total Adult Prevalent cases, Gender Specific Prevalent Cases, Severity Specific Prevalent Cases and Prevalence of Clinical Manifestations of OSA) scenario of Obstructive Sleep Apnea (OSA) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the total number of adult prevalent population of Obstructive Sleep Apnea (OSA) in 7 MM was found to be 1,381,527, in the year 2016.
Obstructive Sleep Apnea Drug Chapters
This segment of the Obstructive Sleep Apnea report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Current treatment landscape of OSA mainly comprises of options including continuous positive airway pressure (CPAP), oral appliances therapy, surgery, and lifestyle changes such as weight loss or body positioning during sleep. Among all these, CPAP is the gold standard treatment for OSA and occupies the largest market share (devices). Mandibular advancement splints are another treatment modality for OSA which is considered as the second line of treatment for OSA. However CPAP is not the only medical device approved for treatment of OSA. On May 1, 2014, FDA approved the first implanted medical device for the treatment of this disorder.
Provigil Oral and Nuvigil Oral are the only approved marketed drugs for OSA in the US. They both are indicated as an adjunct to standard treatment(s) for the underlying obstruction except in the EU5 where it has been withdrawn following an EMA directive in 2010. Detailed chapter for upcoming therapies like Solriamfetol (also known as JZP-110/SKL-N05) (Jazz Pharmaceuticals), and Dronabinol (RespireRx) have been covered in the report.
Obstructive Sleep Apnea Market Outlook
The Obstructive Sleep Apnea market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Obstructive Sleep Apnea in 7MM was found to be USD 197.46 million in 2016, and is expected to increase from 2016-2027.
Obstructive Sleep Apnea Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Obstructive Sleep Apnea Report Insights
DelveInsight’s ‘Obstructive Sleep Apnea (OSA)- Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Obstructive Sleep Apnea (OSA) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Obstructive Sleep Apnea (OSA) - Disease Understanding and Treatment Algorithm
The DelveInsight Obstructive Sleep Apnea (OSA) market report gives the thorough understanding of the Obstructive Sleep Apnea by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Obstructive Sleep Apnea in the US, Europe, and Japan.
Obstructive Sleep Apnea Epidemiology
The Obstructive Sleep Apnea (OSA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Prevalent cases by Age Group, Total Adult Prevalent cases, Gender Specific Prevalent Cases, Severity Specific Prevalent Cases and Prevalence of Clinical Manifestations of OSA) scenario of Obstructive Sleep Apnea (OSA) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the total number of adult prevalent population of Obstructive Sleep Apnea (OSA) in 7 MM was found to be 1,381,527, in the year 2016.
Obstructive Sleep Apnea Drug Chapters
This segment of the Obstructive Sleep Apnea report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Current treatment landscape of OSA mainly comprises of options including continuous positive airway pressure (CPAP), oral appliances therapy, surgery, and lifestyle changes such as weight loss or body positioning during sleep. Among all these, CPAP is the gold standard treatment for OSA and occupies the largest market share (devices). Mandibular advancement splints are another treatment modality for OSA which is considered as the second line of treatment for OSA. However CPAP is not the only medical device approved for treatment of OSA. On May 1, 2014, FDA approved the first implanted medical device for the treatment of this disorder.
Provigil Oral and Nuvigil Oral are the only approved marketed drugs for OSA in the US. They both are indicated as an adjunct to standard treatment(s) for the underlying obstruction except in the EU5 where it has been withdrawn following an EMA directive in 2010. Detailed chapter for upcoming therapies like Solriamfetol (also known as JZP-110/SKL-N05) (Jazz Pharmaceuticals), and Dronabinol (RespireRx) have been covered in the report.
Obstructive Sleep Apnea Market Outlook
The Obstructive Sleep Apnea market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Obstructive Sleep Apnea in 7MM was found to be USD 197.46 million in 2016, and is expected to increase from 2016-2027.
Obstructive Sleep Apnea Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Obstructive Sleep Apnea Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Obstructive Sleep Apnea market
- Organize sales and marketing efforts by identifying the best opportunities for Obstructive Sleep Apnea market
- To understand the future market competition in the Obstructive Sleep Apnea market.
1. KEY INSIGHTS
2. OBSTRUCTIVE SLEEP APNEA (OSA) MARKET OVERVIEW AT A GLANCE
2.1. Market Share (%) Distribution of OSA in 2016
2.2. Market Share (%) Distribution of OSA in 2027
3. OBSTRUCTIVE SLEEP APNEA (OSA): DISEASE OVERVIEW
3.1. Introduction
3.2. Severity Based Classification
3.3. Clinical Manifestations of Obstructive Sleep Apnea
3.4. Etiology
3.5. Risk Factors
3.6. Signs and Symptoms
3.7. Pathogenesis of Obstructive Sleep Apnea
3.8. Diagnosis
3.9. Diagnostic Criteria for OSAS
3.10. Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. Prevalence of OSA by Age Group in 7MM
4.4. Total Prevalence of OSA in Adults in 7MM
5. COUNTRY WISE-EPIDEMIOLOGY OF OBSTRUCTIVE SLEEP APNEA
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalence of OSA by Age Group in the United States
5.1.3. Prevalence of OSA in Adults in the US
5.2. EU5 Countries
5.2.1. Germany
5.2.2. Prevalence of OSA by Age Group in Germany
5.2.3. Prevalence of OSA in Adults in Germany
5.3. France
5.3.1. Prevalence of OSA by Age Group in France
5.3.2. Prevalence of OSA in Adults in France
5.4. Italy
5.4.1. Prevalence of OSA by Age Group in Italy
5.4.2. Prevalence of OSA in Adults in Italy
5.5. Spain
5.5.1. Prevalence of OSA by Age Group in Spain
5.5.2. Prevalence of OSA in Adults in Spain
5.6. United Kingdom
5.6.1. Prevalence of OSA by Age Group in the United Kingdom
5.6.2. Prevalence of OSA in Adults in the United Kingdom
5.7. Japan
5.7.1. Prevalence of OSA by Age Group in Japan
5.7.2. Prevalence of OSA in Adults in Japan
6. CURRENT TREATMENT PRACTICES
7. UNMET NEEDS
8. MARKETED DRUGS
8.1. Key cross competition- Marketed drugs
8.2. Provigil: Teva Pharmaceuticals
8.2.1. Drug Description
8.2.2. Regulatory Milestones
8.2.3. Safety and Efficacy
8.2.4. Product Profile
8.3. Nuvigil: Teva Pharmaceuticals
8.3.1. Drug Description
8.3.2. Regulatory Milestones
8.3.3. Clinical Development
8.3.4. Safety and Efficacy
8.3.5. Product Profile
9. EMERGING THERAPIES
9.1. Key cross competition- Emerging Therapies
9.2. Solriamfetol: Jazz Pharmaceuticals
9.2.1. Product Description
9.2.2. Other Developmental Activities
9.2.3. Clinical Development
9.2.4. Safety and Efficacy
9.2.5. Product Profile
9.3. Dronabinol: RespireRx Pharmaceuticals
9.3.1. Product Description
9.3.2. Other Developmental Activities
9.3.3. Clinical Development
9.3.4. Safety and Efficacy
9.3.5. Advantages and Disadvantages
9.3.6. Product Profile
10. OBSTRUCTIVE SLEEP APNEA: 7 MAJOR MARKET ANALYSIS
10.1. Key Findings
10.2. Market Size of Obstructive Sleep Apnea in 7MM
10.3. Therapy Based Market Size of Obstructive Sleep Apnea in 7MM
11. MARKET OUTLOOK BY COUNTRY
12. THE UNITED STATES: MARKET OUTLOOK
12.1. United States Market Size
12.1.1. Total Market size of Obstructive Sleep Apnea
12.1.2. Therapy Based Market Size of OSA in the US
13. EU-5 COUNTRIES: MARKET OUTLOOK
13.1. Germany
13.1.1. Total Market size of Obstructive Sleep Apnea
13.1.2. Therapy Based Market Size of OSA in Germany
13.2. France
13.2.1. Total Market size of Obstructive Sleep Apnea in France
13.2.2. Therapy Based Market Size of OSA in France
13.3. Italy
13.3.1. Total Market size of Obstructive Sleep Apnea in Italy
13.3.2. Therapy Based Market Size of OSA in Italy
13.4. Spain
13.4.1. Total Market size of Obstructive Sleep Apnea in Spain
13.4.2. Therapy Based Market Size of OSA in Spain
13.5. United Kingdom
13.5.1. Total Market size of Obstructive Sleep Apnea in the UK
13.5.2. Therapy Based Market Size of OSA in the United Kingdom
13.6. Japan: Market Outlook
13.6.1. Total Market size of Obstructive Sleep Apnea in Japan
13.6.2. Therapy Based Market Size of OSA in Japan
14. MARKET DRIVERS
15. MARKET BARRIERS
16. APPENDIX
16.1. Report Methodology
17. DELVEINSIGHT CAPABILITIES
18. DISCLAIMER
19. ABOUT DELVEINSIGHT
2. OBSTRUCTIVE SLEEP APNEA (OSA) MARKET OVERVIEW AT A GLANCE
2.1. Market Share (%) Distribution of OSA in 2016
2.2. Market Share (%) Distribution of OSA in 2027
3. OBSTRUCTIVE SLEEP APNEA (OSA): DISEASE OVERVIEW
3.1. Introduction
3.2. Severity Based Classification
3.3. Clinical Manifestations of Obstructive Sleep Apnea
3.4. Etiology
3.5. Risk Factors
3.6. Signs and Symptoms
3.7. Pathogenesis of Obstructive Sleep Apnea
3.8. Diagnosis
3.9. Diagnostic Criteria for OSAS
3.10. Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. Prevalence of OSA by Age Group in 7MM
4.4. Total Prevalence of OSA in Adults in 7MM
5. COUNTRY WISE-EPIDEMIOLOGY OF OBSTRUCTIVE SLEEP APNEA
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalence of OSA by Age Group in the United States
5.1.3. Prevalence of OSA in Adults in the US
5.2. EU5 Countries
5.2.1. Germany
5.2.2. Prevalence of OSA by Age Group in Germany
5.2.3. Prevalence of OSA in Adults in Germany
5.3. France
5.3.1. Prevalence of OSA by Age Group in France
5.3.2. Prevalence of OSA in Adults in France
5.4. Italy
5.4.1. Prevalence of OSA by Age Group in Italy
5.4.2. Prevalence of OSA in Adults in Italy
5.5. Spain
5.5.1. Prevalence of OSA by Age Group in Spain
5.5.2. Prevalence of OSA in Adults in Spain
5.6. United Kingdom
5.6.1. Prevalence of OSA by Age Group in the United Kingdom
5.6.2. Prevalence of OSA in Adults in the United Kingdom
5.7. Japan
5.7.1. Prevalence of OSA by Age Group in Japan
5.7.2. Prevalence of OSA in Adults in Japan
6. CURRENT TREATMENT PRACTICES
7. UNMET NEEDS
8. MARKETED DRUGS
8.1. Key cross competition- Marketed drugs
8.2. Provigil: Teva Pharmaceuticals
8.2.1. Drug Description
8.2.2. Regulatory Milestones
8.2.3. Safety and Efficacy
8.2.4. Product Profile
8.3. Nuvigil: Teva Pharmaceuticals
8.3.1. Drug Description
8.3.2. Regulatory Milestones
8.3.3. Clinical Development
8.3.4. Safety and Efficacy
8.3.5. Product Profile
9. EMERGING THERAPIES
9.1. Key cross competition- Emerging Therapies
9.2. Solriamfetol: Jazz Pharmaceuticals
9.2.1. Product Description
9.2.2. Other Developmental Activities
9.2.3. Clinical Development
9.2.4. Safety and Efficacy
9.2.5. Product Profile
9.3. Dronabinol: RespireRx Pharmaceuticals
9.3.1. Product Description
9.3.2. Other Developmental Activities
9.3.3. Clinical Development
9.3.4. Safety and Efficacy
9.3.5. Advantages and Disadvantages
9.3.6. Product Profile
10. OBSTRUCTIVE SLEEP APNEA: 7 MAJOR MARKET ANALYSIS
10.1. Key Findings
10.2. Market Size of Obstructive Sleep Apnea in 7MM
10.3. Therapy Based Market Size of Obstructive Sleep Apnea in 7MM
11. MARKET OUTLOOK BY COUNTRY
12. THE UNITED STATES: MARKET OUTLOOK
12.1. United States Market Size
12.1.1. Total Market size of Obstructive Sleep Apnea
12.1.2. Therapy Based Market Size of OSA in the US
13. EU-5 COUNTRIES: MARKET OUTLOOK
13.1. Germany
13.1.1. Total Market size of Obstructive Sleep Apnea
13.1.2. Therapy Based Market Size of OSA in Germany
13.2. France
13.2.1. Total Market size of Obstructive Sleep Apnea in France
13.2.2. Therapy Based Market Size of OSA in France
13.3. Italy
13.3.1. Total Market size of Obstructive Sleep Apnea in Italy
13.3.2. Therapy Based Market Size of OSA in Italy
13.4. Spain
13.4.1. Total Market size of Obstructive Sleep Apnea in Spain
13.4.2. Therapy Based Market Size of OSA in Spain
13.5. United Kingdom
13.5.1. Total Market size of Obstructive Sleep Apnea in the UK
13.5.2. Therapy Based Market Size of OSA in the United Kingdom
13.6. Japan: Market Outlook
13.6.1. Total Market size of Obstructive Sleep Apnea in Japan
13.6.2. Therapy Based Market Size of OSA in Japan
14. MARKET DRIVERS
15. MARKET BARRIERS
16. APPENDIX
16.1. Report Methodology
17. DELVEINSIGHT CAPABILITIES
18. DISCLAIMER
19. ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: Prevalent Population of Obstructive Sleep Apnea in the 7MM (2016-2027)
Table 2: Total Adult Cases of Obstructive Sleep Apnea in the 7MM (2016-2027)
Table 3: Gender-specific Prevalent Cases of Obstructive Sleep Apnea in the United States (2016-2027)
Table 4: Prevalence of OSA in Adults in the United States (2016-2027)
Table 5: Gender Specific Prevalence of Obstructive Sleep Apnea in the United States (2016-2027)
Table 6: Severity-specific Prevalent Cases of Obstructive Sleep Apnea in the United States (2016-2027)
Table 7: Prevalence of Clinical Manifestation of OSA in Adults in the United States (2016-2027)
Table 8: Prevalence of Obstructive Sleep Apnea in Germany by Age Group (2016-2027)
Table 9: Total Prevalence of Obstructive Sleep Apnea in Adults in Germany (2016-2027)
Table 10: Gender Specific Prevalence of Obstructive Sleep Apnea in Adults in Germany (2016-2027)
Table 11: Severity specific prevalent cases of Obstructive Sleep Apnea in Germany (2016-2027)
Table 12: Prevalence of Clinical Manifestation of OSA in Adults in Germany (2016-2027)
Table 13: Age Specific Prevalence of Obstructive Sleep Apnea in France (2016-2027)
Table 14: Total Prevalence of Obstructive Sleep Apnea in France (2016-2027)
Table 15: Gender-specific Prevalent Cases of Obstructive Sleep Apnea in France (2016-2027)
Table 16: Severity Specific Prevalence of Obstructive Sleep Apnea in France (2016-2027)
Table 17: Prevalence of Clinical Manifestation of OSA in Adults in France (2016-2027)
Table 18: Prevalent Cases of Obstructive Sleep Apnea By Age Group in Italy (2016-2027)
Table 19: Prevalent Cases of Obstructive Sleep Apnea By Age Group in Italy (2016-2027)
Table 20: Total Prevalence of Obstructive Sleep Apnea in Adults in Italy (2016-2027)
Table 21: Total Prevalence of Obstructive Sleep Apnea in Adults in Italy (2016-2027)
Table 22: Gender-specific Prevalence of Obstructive Sleep Apnea in Italy (2016-2027)
Table 23: Gender-specific Prevalence of Obstructive Sleep Apnea in Italy (2016-2027)
Table 24: Severity specific Prevalent Cases of Obstructive Sleep Apnea in Italy (2016-2027)
Table 25: Severity specific Prevalent Cases of Obstructive Sleep Apnea in Italy (2016-2027)
Table 26: Prevalence of Clinical Manifestation of OSA in Adults in Italy (2016-2027)
Table 27: Prevalence of Clinical Manifestation of OSA in Adults in Italy (2016-2027)
Table 28: Prevalent Cases of Obstructive Sleep Apnea in Spain (2016-2027)
Table 29: Total Prevalence of Obstructive Sleep Apnea in Adults in Spain (2016-2027)
Table 30: Gender Specific Prevalence of Obstructive Sleep Apnea in Spain (2016-2027)
Table 31: Severity specific Prevalent Cases of Obstructive Sleep Apnea in Spain (2016-2027)
Table 32: Prevalence of Clinical Manifestation of OSA in Adults in Spain (2016-2027)
Table 33: Prevalent Cases of Obstructive Sleep Apnea in the United Kingdom (2016-2027)
Table 34: Total Prevalence of Obstructive Sleep Apnea in Adults the United Kingdom (2016-2027)
Table 35: Gender Specific Prevalence of OSA in the United Kingdom (2016-2027)
Table 36: Severity specific Prevalent Cases of Obstructive Sleep Apnea in the UK (2016-2027)
Table 37: Prevalence of Clinical Manifestation of OSA in Adults in the UK (2016-2027)
Table 38: Age Group Specific Prevalence of Obstructive Sleep Apnea in Japan (2016-2027)
Table 39: Total Prevalence of Obstructive Sleep Apnea in Adults Japan (2016-2027)
Table 40: Gender Specific Prevalence of Obstructive Sleep Apnea in Japan (2016-2027)
Table 41: Severity specific Prevalent Cases of Obstructive Sleep Apnea in Japan (2016-2027)
Table 42: Prevalence of Clinical Manifestation of OSA in Adults in Japan (2016-2027)
Table 43: Provigil, Clinical Trial Description, 2018
Table 44: Key cross competition- Emerging Therapies
Table 45: Solriamfetol, Clinical Trial Description, 2018
Table 46: 7 Major Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 47: Therapy-Based Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 48: United States Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 49: Therapy Based Market Size of OSA in the US in USD Million (2016-2027)
Table 50: Germany Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 51: Therapy Based Market Size of OSA in Germany in USD Million (2016-2027)
Table 52: France Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 53: Therapy Based Market Size of OSA in France in USD Million (2016-2027)
Table 54: Italy Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 55: Therapy Based Market Size of OSA in Italy in USD Million (2016-2027)
Table 56: Spain Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 57: Therapy Based Market Size of OSA in Spain in USD Million (2016-2027)
Table 58: United Kingdom Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 59: Therapy Based Market Size of OSA in the UK in USD Million (2016-2027)
Table 60: Japan Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 61:Therapy Based Market Size of OSA in Japan in USD Million (2016-2027)
Table 1: Prevalent Population of Obstructive Sleep Apnea in the 7MM (2016-2027)
Table 2: Total Adult Cases of Obstructive Sleep Apnea in the 7MM (2016-2027)
Table 3: Gender-specific Prevalent Cases of Obstructive Sleep Apnea in the United States (2016-2027)
Table 4: Prevalence of OSA in Adults in the United States (2016-2027)
Table 5: Gender Specific Prevalence of Obstructive Sleep Apnea in the United States (2016-2027)
Table 6: Severity-specific Prevalent Cases of Obstructive Sleep Apnea in the United States (2016-2027)
Table 7: Prevalence of Clinical Manifestation of OSA in Adults in the United States (2016-2027)
Table 8: Prevalence of Obstructive Sleep Apnea in Germany by Age Group (2016-2027)
Table 9: Total Prevalence of Obstructive Sleep Apnea in Adults in Germany (2016-2027)
Table 10: Gender Specific Prevalence of Obstructive Sleep Apnea in Adults in Germany (2016-2027)
Table 11: Severity specific prevalent cases of Obstructive Sleep Apnea in Germany (2016-2027)
Table 12: Prevalence of Clinical Manifestation of OSA in Adults in Germany (2016-2027)
Table 13: Age Specific Prevalence of Obstructive Sleep Apnea in France (2016-2027)
Table 14: Total Prevalence of Obstructive Sleep Apnea in France (2016-2027)
Table 15: Gender-specific Prevalent Cases of Obstructive Sleep Apnea in France (2016-2027)
Table 16: Severity Specific Prevalence of Obstructive Sleep Apnea in France (2016-2027)
Table 17: Prevalence of Clinical Manifestation of OSA in Adults in France (2016-2027)
Table 18: Prevalent Cases of Obstructive Sleep Apnea By Age Group in Italy (2016-2027)
Table 19: Prevalent Cases of Obstructive Sleep Apnea By Age Group in Italy (2016-2027)
Table 20: Total Prevalence of Obstructive Sleep Apnea in Adults in Italy (2016-2027)
Table 21: Total Prevalence of Obstructive Sleep Apnea in Adults in Italy (2016-2027)
Table 22: Gender-specific Prevalence of Obstructive Sleep Apnea in Italy (2016-2027)
Table 23: Gender-specific Prevalence of Obstructive Sleep Apnea in Italy (2016-2027)
Table 24: Severity specific Prevalent Cases of Obstructive Sleep Apnea in Italy (2016-2027)
Table 25: Severity specific Prevalent Cases of Obstructive Sleep Apnea in Italy (2016-2027)
Table 26: Prevalence of Clinical Manifestation of OSA in Adults in Italy (2016-2027)
Table 27: Prevalence of Clinical Manifestation of OSA in Adults in Italy (2016-2027)
Table 28: Prevalent Cases of Obstructive Sleep Apnea in Spain (2016-2027)
Table 29: Total Prevalence of Obstructive Sleep Apnea in Adults in Spain (2016-2027)
Table 30: Gender Specific Prevalence of Obstructive Sleep Apnea in Spain (2016-2027)
Table 31: Severity specific Prevalent Cases of Obstructive Sleep Apnea in Spain (2016-2027)
Table 32: Prevalence of Clinical Manifestation of OSA in Adults in Spain (2016-2027)
Table 33: Prevalent Cases of Obstructive Sleep Apnea in the United Kingdom (2016-2027)
Table 34: Total Prevalence of Obstructive Sleep Apnea in Adults the United Kingdom (2016-2027)
Table 35: Gender Specific Prevalence of OSA in the United Kingdom (2016-2027)
Table 36: Severity specific Prevalent Cases of Obstructive Sleep Apnea in the UK (2016-2027)
Table 37: Prevalence of Clinical Manifestation of OSA in Adults in the UK (2016-2027)
Table 38: Age Group Specific Prevalence of Obstructive Sleep Apnea in Japan (2016-2027)
Table 39: Total Prevalence of Obstructive Sleep Apnea in Adults Japan (2016-2027)
Table 40: Gender Specific Prevalence of Obstructive Sleep Apnea in Japan (2016-2027)
Table 41: Severity specific Prevalent Cases of Obstructive Sleep Apnea in Japan (2016-2027)
Table 42: Prevalence of Clinical Manifestation of OSA in Adults in Japan (2016-2027)
Table 43: Provigil, Clinical Trial Description, 2018
Table 44: Key cross competition- Emerging Therapies
Table 45: Solriamfetol, Clinical Trial Description, 2018
Table 46: 7 Major Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 47: Therapy-Based Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 48: United States Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 49: Therapy Based Market Size of OSA in the US in USD Million (2016-2027)
Table 50: Germany Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 51: Therapy Based Market Size of OSA in Germany in USD Million (2016-2027)
Table 52: France Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 53: Therapy Based Market Size of OSA in France in USD Million (2016-2027)
Table 54: Italy Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 55: Therapy Based Market Size of OSA in Italy in USD Million (2016-2027)
Table 56: Spain Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 57: Therapy Based Market Size of OSA in Spain in USD Million (2016-2027)
Table 58: United Kingdom Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 59: Therapy Based Market Size of OSA in the UK in USD Million (2016-2027)
Table 60: Japan Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Table 61:Therapy Based Market Size of OSA in Japan in USD Million (2016-2027)
LIST OF FIGURES
Figure 1: Sleep Apnea
Figure 2: Apnea / hypopnea cycle
Figure 3: Pathological relationship between sleep apnea and cardiovascular disease
Figure 4: Risk Factors for Obstructive Sleep Apnea
Figure 5: Clinical algorithm for implementation of clinical practice guidelines.
Figure 6: Prevalent Population of Obstructive Sleep Apnea in the 7MM (2016-2027)
Figure 7: Total Adult OSA Cases in 7MM (2016-2027)
Figure 8: Prevalence of Obstructive Sleep Apnea by Age Group in the United States (2016-2027)
Figure 9: Prevalence of OSA in Adults in the United States (2016-2027)
Figure 10: Gender Specific Prevalence of Obstructive Sleep Apnea in the United States (2016-2027)
Figure 11: Severity-specific Prevalent Cases of Obstructive Sleep Apnea in the United States (2016-2027)
Figure 12: Prevalence of Clinical Manifestation of OSA in Adults in the United States (2016-2027)
Figure 13: Prevalence of Obstructive Sleep Apnea in Germany by Age Group (2016-2027)
Figure 14: Total Prevalence of Obstructive Sleep Apnea in Adults in Germany (2016-2027)
Figure 15: Gender Specific Prevalence of Obstructive Sleep Apnea in Adults in Germany (2016-2027)
Figure 16: Severity specific prevalent cases of Obstructive Sleep Apnea in Germany (2016-2027)
Figure 17: Prevalence of Clinical Manifestation of OSA in Adults in Germany (2016-2027)
Figure 18: Prevalence of Obstructive Sleep Apnea in France by Age Group (2016-2027)
Figure 19: Total Prevalence of Obstructive Sleep Apnea in Adults in France (2016-2027)
Figure 20: Gender-specific Prevalent Cases of Obstructive Sleep Apnea in France (2016-2027)
Figure 21: Severity Specific Prevalence of Obstructive Sleep Apnea in France (2016-2027)
Figure 22: Prevalence of Clinical Manifestation of OSA in Adults in Germany (2016-2027)
Figure 23: Prevalence of Obstructive Sleep Apnea by Age Group in Spain (2016-2027)
Figure 24: Total Prevalence of Obstructive Sleep Apnea in Adults in Spain (2016-2027)
Figure 25: Gender Specific Prevalence of Obstructive Sleep Apnea in Spain (2016-2027)
Figure 26: Severity specific Prevalent Cases of Obstructive Sleep Apnea in Spain (2016-2027)
Figure 27: Prevalence of Clinical Manifestation of OSA in Adults in Spain (2016-2027)
Figure 28: Prevalent Cases of Obstructive Sleep Apnea in the United Kingdom (2016-2027)
Figure 29: Total Prevalence of Obstructive Sleep Apnea in Adults the United Kingdom (2016-2027)
Figure 30: Gender Specific Prevalence of OSA in the United Kingdom (2016-2027)
Figure 31: Severity specific Prevalent Cases of Obstructive Sleep Apnea in the United Kingdom (2016-2027)
Figure 32: Prevalence of Clinical Manifestation of OSA in Adults in the UK (2016-2027)
Figure 33: Age Group Specific Prevalence of Obstructive Sleep Apnea in Japan (2016-2027)
Figure 34: Total Prevalence of Obstructive Sleep Apnea in Adults Japan (2016-2027)
Figure 35: Gender Specific Prevalence of Obstructive Sleep Apnea in Japan (2016-2027)
Figure 36: Severity specific Prevalent Cases of Obstructive Sleep Apnea in Japan (2016-2027)
Figure 37: Prevalence of Clinical Manifestation of OSA in Adults in Japan(2016-2027)
Figure 38: Unmet Needs for Obstructive Sleep Apnea
Figure 39: 7 Major Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Figure 40: Therapy Based Market Size of OSA in 7MM in USD Million (2016-2027)
Figure 41: Market Size of Obstructive Sleep Apnea in the United States, USD Millions (2016-2027)
Figure 42: Therapy Based Market Size of OSA in USD Million (2016-2027)
Figure 43: Market Size of Obstructive Sleep Apnea in Germany, USD Millions (2016-2027)
Figure 44: Therapy Based Market Size of OSA in USD Million (2016-2027)
Figure 45: Market Size of Obstructive Sleep Apnea in France USD Millions (2016-2027)
Figure 46: Therapy Based Market Size of OSA in USD Million (2016-2027)
Figure 47: Market Size of Obstructive Sleep Apnea in Italy, USD Millions (2016-2027)
Figure 48: Therapy Based Market Size of OSA in USD Million (2016-2027)
Figure 49: Market Size of Obstructive Sleep Apnea in Spain, USD Millions (2016-2027)
Figure 50: Therapy Based Market Size of OSA in USD Million (2016-2027)
Figure 51: Market Size of Obstructive Sleep Apnea in the UK, USD Millions (2016-2027)
Figure 52: Therapy Based Market Size of OSA in USD Million (2016-2027)
Figure 53: Market Size of Obstructive Sleep Apnea in the UK, USD Millions (2016-2027)
Figure 54: Therapy Based Market Size of OSA in USD Million (2016-2027)
Figure 55: Market Drivers
Figure 56: Market Barriers
Figure 1: Sleep Apnea
Figure 2: Apnea / hypopnea cycle
Figure 3: Pathological relationship between sleep apnea and cardiovascular disease
Figure 4: Risk Factors for Obstructive Sleep Apnea
Figure 5: Clinical algorithm for implementation of clinical practice guidelines.
Figure 6: Prevalent Population of Obstructive Sleep Apnea in the 7MM (2016-2027)
Figure 7: Total Adult OSA Cases in 7MM (2016-2027)
Figure 8: Prevalence of Obstructive Sleep Apnea by Age Group in the United States (2016-2027)
Figure 9: Prevalence of OSA in Adults in the United States (2016-2027)
Figure 10: Gender Specific Prevalence of Obstructive Sleep Apnea in the United States (2016-2027)
Figure 11: Severity-specific Prevalent Cases of Obstructive Sleep Apnea in the United States (2016-2027)
Figure 12: Prevalence of Clinical Manifestation of OSA in Adults in the United States (2016-2027)
Figure 13: Prevalence of Obstructive Sleep Apnea in Germany by Age Group (2016-2027)
Figure 14: Total Prevalence of Obstructive Sleep Apnea in Adults in Germany (2016-2027)
Figure 15: Gender Specific Prevalence of Obstructive Sleep Apnea in Adults in Germany (2016-2027)
Figure 16: Severity specific prevalent cases of Obstructive Sleep Apnea in Germany (2016-2027)
Figure 17: Prevalence of Clinical Manifestation of OSA in Adults in Germany (2016-2027)
Figure 18: Prevalence of Obstructive Sleep Apnea in France by Age Group (2016-2027)
Figure 19: Total Prevalence of Obstructive Sleep Apnea in Adults in France (2016-2027)
Figure 20: Gender-specific Prevalent Cases of Obstructive Sleep Apnea in France (2016-2027)
Figure 21: Severity Specific Prevalence of Obstructive Sleep Apnea in France (2016-2027)
Figure 22: Prevalence of Clinical Manifestation of OSA in Adults in Germany (2016-2027)
Figure 23: Prevalence of Obstructive Sleep Apnea by Age Group in Spain (2016-2027)
Figure 24: Total Prevalence of Obstructive Sleep Apnea in Adults in Spain (2016-2027)
Figure 25: Gender Specific Prevalence of Obstructive Sleep Apnea in Spain (2016-2027)
Figure 26: Severity specific Prevalent Cases of Obstructive Sleep Apnea in Spain (2016-2027)
Figure 27: Prevalence of Clinical Manifestation of OSA in Adults in Spain (2016-2027)
Figure 28: Prevalent Cases of Obstructive Sleep Apnea in the United Kingdom (2016-2027)
Figure 29: Total Prevalence of Obstructive Sleep Apnea in Adults the United Kingdom (2016-2027)
Figure 30: Gender Specific Prevalence of OSA in the United Kingdom (2016-2027)
Figure 31: Severity specific Prevalent Cases of Obstructive Sleep Apnea in the United Kingdom (2016-2027)
Figure 32: Prevalence of Clinical Manifestation of OSA in Adults in the UK (2016-2027)
Figure 33: Age Group Specific Prevalence of Obstructive Sleep Apnea in Japan (2016-2027)
Figure 34: Total Prevalence of Obstructive Sleep Apnea in Adults Japan (2016-2027)
Figure 35: Gender Specific Prevalence of Obstructive Sleep Apnea in Japan (2016-2027)
Figure 36: Severity specific Prevalent Cases of Obstructive Sleep Apnea in Japan (2016-2027)
Figure 37: Prevalence of Clinical Manifestation of OSA in Adults in Japan(2016-2027)
Figure 38: Unmet Needs for Obstructive Sleep Apnea
Figure 39: 7 Major Market Size of Obstructive Sleep Apnea in USD Million (2016-2027)
Figure 40: Therapy Based Market Size of OSA in 7MM in USD Million (2016-2027)
Figure 41: Market Size of Obstructive Sleep Apnea in the United States, USD Millions (2016-2027)
Figure 42: Therapy Based Market Size of OSA in USD Million (2016-2027)
Figure 43: Market Size of Obstructive Sleep Apnea in Germany, USD Millions (2016-2027)
Figure 44: Therapy Based Market Size of OSA in USD Million (2016-2027)
Figure 45: Market Size of Obstructive Sleep Apnea in France USD Millions (2016-2027)
Figure 46: Therapy Based Market Size of OSA in USD Million (2016-2027)
Figure 47: Market Size of Obstructive Sleep Apnea in Italy, USD Millions (2016-2027)
Figure 48: Therapy Based Market Size of OSA in USD Million (2016-2027)
Figure 49: Market Size of Obstructive Sleep Apnea in Spain, USD Millions (2016-2027)
Figure 50: Therapy Based Market Size of OSA in USD Million (2016-2027)
Figure 51: Market Size of Obstructive Sleep Apnea in the UK, USD Millions (2016-2027)
Figure 52: Therapy Based Market Size of OSA in USD Million (2016-2027)
Figure 53: Market Size of Obstructive Sleep Apnea in the UK, USD Millions (2016-2027)
Figure 54: Therapy Based Market Size of OSA in USD Million (2016-2027)
Figure 55: Market Drivers
Figure 56: Market Barriers
